Global reported endophthalmitis risk following intravitreal injections of anti-VEGF: a literature review and analysis.

ABSTRACT:

Purpose

To report on endophthalmitis occurrence and associated risk factors following the intravitreal injection of anti-VEGF agents based on a review of published literature.

Materials and methods

A Medline search was performed using the terms "bevacizumab" and "ranibizumab". A total of 534 English-language articles of varying design and published from 2006 to November 2013 were analyzed for endophthalmitis occurrence and contributing perioperative factors.

Results

A total of 445,503 injections were counted. There were 103 cases of postinjection endophthalmitis in 176,124 injections (0.058%) with bevacizumab (Avastin) versus 79 cases in 269,379 injections (0.029%) with ranibizumab (Lucentis). This difference was due to a significantly higher occurrence of culture-neg

SUBMITTER: Sigford DK 

PROVIDER: S-EPMC4427080 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature